Introduction
============

Esophageal carcinoma (ESCA) is one of the most common types of cancer in the digestive system which primarily includes esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma ([@b1-ijo-54-01-0152]). According to recent statistics, estimated new cases of and mortality from ESCA account for a large proportion of all cancer in the USA ([@b2-ijo-54-01-0152]). ESCA also ranks in the top ten of cancer incidence and mortality rate worldwide, which is associated with genetic and environmental factors ([@b3-ijo-54-01-0152]). In addition, patients with ESCA have a poor prognosis and high mortality rate that may be associated with glucose-regulated protein 78 ([@b4-ijo-54-01-0152],[@b5-ijo-54-01-0152]).

At present, several methods are practiced in clinical treatment for ESCA ([@b6-ijo-54-01-0152]). Surgical resection is commonly used to remove cancerous tissue and leads to an improved survival rate. Neoadjuvant chemotherapy (without radiation therapy) provides an improved survival benefit compared with surgery alone ([@b7-ijo-54-01-0152]), but the effects on local control are unclear. Tri-modality treatment (concomitant chemotherapy and radiation therapy followed by surgery) also has a marked effect compared with surgery alone ([@b5-ijo-54-01-0152]). Additionally, several chemotherapy target agents for ESCA have been reported, including fluoropyrimidines \[5-fluorouracil (5-FU) and capecitabine\], platinum agents (cisplatin and oxaliplatin), taxanes (paclitaxel and docetaxel), irinotecan, mitomycin-C, anthracyclines, methotrexate, vinorelbine and gemcitabine. The combination of two or more drugs has a more marked reaction, as it has been reported to increase the efficacy of chemoradiotherapy in patients with ESCA ([@b8-ijo-54-01-0152]-[@b10-ijo-54-01-0152]). However, intolerance of fluoropyrimidine-based, platinum-based and taxane-based chemotherapy has also been identified in patients, and immune checkpoint blockade therapy remains under investigation ([@b11-ijo-54-01-0152]). Therefore, further research is required for more effective therapeutic methods.

Gene-associated therapy for cancers has become a research focus in recent years ([@b12-ijo-54-01-0152]-[@b16-ijo-54-01-0152]). With regard to ESCA, it was identified that the aberrant transcription and translation of genes affect the synthesis of associated proteins, which has an effect on the corresponding physiological processes, and consequently influences the diagnosis and prognosis of ESCA ([@b17-ijo-54-01-0152]-[@b19-ijo-54-01-0152]). It was also identified that the chemotherapeutic mechanism of ESCA was associated with upregulation and downregulation of genes or DNA repair genes ([@b20-ijo-54-01-0152],[@b21-ijo-54-01-0152]). In addition, gene levels and certain signaling pathways were identified to be associated with chemotherapy resistance ([@b22-ijo-54-01-0152],[@b23-ijo-54-01-0152]). For example, it was reported that the expression of myeloid cell leukemia 1 in ESCA cancerous tissue with cisplatin resistance increased in comparison with that in normal tissue ([@b24-ijo-54-01-0152]). Let-7 was also identified to serve a potentially positive function in patients with 5-FU resistance ([@b25-ijo-54-01-0152]), which indicates that the drugs targeted in these pathways or genes are potential candidates for improved treatment. Generally, differentially expressed genes (DEGs) and signaling pathways may be the fundamental reason for the development of ESCA. Thus, research into the biological significance of target genes and their corresponding signaling pathways is required for gene-associated chemotherapy.

However, specific drugs mapped to the target genes and their associated pathways remain unknown. Thus, the aim of the present study was to predict novel drug candidates of ESCA using bioinformatics analysis, which was principally based on the Connectivity Map (CMAP), a database that contains 1,309 Food and Drug Administration-approved small molecules and 7,000 gene expression profiles, and has been widely used to reveal the mechanism of drugs ([@b26-ijo-54-01-0152]). Furthermore, molecular virtual docking was used in the search for matching predicted potential drugs and screened proteins. To a certain extent, the present study may provide a new point of reference for chemotherapy for ESCA, with regard to its molecular biology and the methodology.

Materials and methods
=====================

Acquisition of DEGs in ESCA
---------------------------

To acquire the information of gene expression levels in ESCA, the gene expression data of ESCA were downloaded from The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) ([@b27-ijo-54-01-0152]), and the edition of TCGA dataset on ESCA was updated on October 13, 2017. The gene expression data of ESCA were normalized into the transcripts per million reads format. The differential expression analysis was further performed on the basis of the normalized data and analysis of variance (ANOVA), which was used for tumor vs. paired normal samples. For the differential analysis methods of ANOVA, genes with \|log~2~ fold-change (FC)\|≥2 and q-value \<0.05 were considered to be DEGs.

Analysis of DEGs associated with ESCA
-------------------------------------

### Functional analysis of differentially expressed genes

WEB-based GEne SeT AnaLysis Toolkit (Webgestalt; [www.webgestalt.org](http://www.webgestalt.org)) was used to explain the function of extracted DEGs with an enrichment method of over-representation (enrichment) analysis. Gene Ontology (GO) enrichment analysis was performed to classify the genes into their Biological Process (BP), Cellular Component (CC) and Molecular Function (MF) categories. The Kyoto Encyclopedia of Genes and Genomes (KEGG) ([www.kegg.jp](http://www.kegg.jp)) and Protein Annotation Through Evolutionary Relationships (PANTHER) ([www.pantherdb.org](http://www.pantherdb.org)) analyses were performed to determine the pathways in which the DEGs were significantly involved ([@b28-ijo-54-01-0152]-[@b30-ijo-54-01-0152]).

### Excavation of hub genes of ESCA

For further understanding of genes that may have a significant effect on ESCA, the protein-protein interaction (PPI) network was then drafted via Search Tool for the Retrieval of Interacting Genes (STRING; [string-db.org](http://string-db.org)). The interaction between two nodes, which represent two genes, was confirmed using Textmining, Experiments, Databases, Co-expression, Neighborhood, Gene Fusion and Co-occurrence. Degrees of edges were calculated using Cytoscape ([@b29-ijo-54-01-0152],[@b31-ijo-54-01-0152]-[@b34-ijo-54-01-0152]). Finally, the genes with a degree of ≥30 were selected to be hub genes of ESCA, which were considered to be potential bioactive factors for ESCA and were further involved in the subsequent research.

Prediction of ESCA-associated drugs and extraction of relevant target genes
---------------------------------------------------------------------------

### Drug prediction of ESCA based on CMAP

CMAP (portals. [broadinstitute.org/cmap](http://broadinstitute.org/cmap)) ([@b26-ijo-54-01-0152],[@b28-ijo-54-01-0152]) was selected to predict the potential drug molecules for ESCA. Following ID conversion via Affymetrix ([www.affymetrix.com/analysis/index.affx](http://www.affymetrix.com/analysis/index.affx)), the upregulated and downregulated DEGs were uploaded to CMAP for online analysis. Detailed results from CMAP were downloaded, and the first screening drugs were further acquired following filtering for a score of \<−0.85.

### Extraction of target genes for the first screening drugs

To further screen out more significant drug molecules and prepare for the following investigation of potential drug-associated mechanisms in ESCA, the Search Tool for Interactions of Chemicals (STITCH, stitch.embl.de), a protein-compound interactions database that contains 390,000 compounds and 3.6 million proteins, was used in which the Canonical Simplified Molecular-Input Line-Entry System (SMILES) structure of drugs downloaded from PubChem (pubchem.ncbi.nlm.nih. gov) were uploaded in order to search for target genes. In this way, the second screening drugs were extracted when the drugs without STITCH-predicted results were phased out, and their corresponding target genes were obtained. Additionally, intersection between predicted target genes and the extracted DEGs of ESCA was calculated using FunRich ([@b35-ijo-54-01-0152]) for a preliminary understanding of their associations.

### Interaction analysis of drug candidates-target genes-ESCA- associated hub genes

To investigate the associations between the predicted drugs and hub genes of ESCA, the target genes of drugs and hub genes of ESCA were analyzed. First, another PPI network was constructed to analyze the interactions between the two sources of genes aforementioned. Connected nodes, confirmed by experiments and databases, were identified and were considered to be associated genes. The unconnected nodes were not included in the following investigation and their corresponding drugs were eliminated. Up to this point, all the extant drugs were considered to be drug candidates of ESCA in the present study. Furthermore, genes confirmed by PPI were then used for constructing the network of drug candidates-target genes-ESCA-associated hub genes. Further analysis of the selected genes was performed using the same methods as for the aforementioned functional analysis of DEGs of ESCA.

### Molecular docking between predicted drug candidates and hub genes

To further investigate the underlying associations between drugs and hub genes in the drug candidates-target genes-ESCA-associated hub genes network, molecular docking was performed using systemsDock (systemsdock.unit.oist. jp/iddp/home/index), which is a web server for network pharmacology-based prediction and analysis ([@b36-ijo-54-01-0152],[@b37-ijo-54-01-0152]). Selected by the second PPI analysis, protein names of the ESCA-associated hub genes in the network were added and specified, then the SMILES structures of drug candidates involved in the network were also uploaded. A protein and a drug were tested each time. The binding affinity between each hub gene and drug groups was predicted by docking scores.

Results
=======

DEGs of ESCA and functional analysis
------------------------------------

A total of 827 DEGs were downloaded from TCGA and GTEx databases with the criteria of \|log2FC\|≥2 and q-value \<0.05 in ANOVA, which includes 375 upregulated genes and 452 downregulated genes ([Fig. 1](#f1-ijo-54-01-0152){ref-type="fig"}). The following KEGG analysis showed that DEGs were significantly involved in 10 pathways (P\<0.005), particularly in protein digestion and absorption, extracellular matrix-receptor interaction and complement, and coagulation cascades ([Table I](#tI-ijo-54-01-0152){ref-type="table"}). A PANTHER analysis indicated that DEGs were significantly involved in five pathways (P\<0.05), among which the plasminogen-activating cascade, blood coagulation and integrin signaling pathway were particularly significant (P\<0.01; [Table II](#tII-ijo-54-01-0152){ref-type="table"}). Classified by GO enrichment analysis, the DEGs were primarily involved in the 'biological regulation', 'metabolic process' and 'response to stimulus' BP categories, and the 'membrane' and 'vesicle' CC categories. They also were involved in the 'nucleus' CC category, and in the 'protein binding', 'ion binding' and 'hydrolase activity' MF categories ([Fig. 2](#f2-ijo-54-01-0152){ref-type="fig"}). Furthermore, 11 genes, including elastin (*ELN*), tissue inhibitor of matrix metalloproteinase 1 (*TIMP1*), intercellular adhesion molecule 1 (*ICAM1*), topoisomerase 2A (*TOP2A*), interleukin 1B (*IL1B*), collagen type I α1 (*COL1A1*), *IL8*, matrix metalloproteinase 9 (*MMP9*), secreted phosphoprotein 1 (*SPP1*), signal transducer and activator of transcription 1 (*STAT1*) and CXC chemokine ligand 10 (*CXCL10*), were finally determined to be hub genes following calculation of the edges based on PPI network analysis (all degrees ≥30) ([Fig. 3](#f3-ijo-54-01-0152){ref-type="fig"}).

ESCA-associated drugs and relevant target genes
-----------------------------------------------

Upregulated and downregulated genes from the TCGA and GTEx databases were uploaded to CMAP, then scores of the predicted ESCA-associated drugs were obtained from the detailed results. Drugs that had a score of \<−0.85 were extracted as the first screening drugs for further research, including verteporfin, apigenin, cefixime, Prestwick-685, menadione, baclofen, dequalinium chloride, butyl hydroxybenzoate, naloxone, paroxetine, acetazolamide, gliclazide, valproic acid and metacycline ([Table III](#tIII-ijo-54-01-0152){ref-type="table"}). Furthermore, Prestwick-685 was categorized as clofazimine by PubChem, whereas dequalinium chloride and butyl hydroxybenzoate were also named dequalinium and butylparaben, respectively. On the basis of STITCH, 70 target genes of 9 second screening drugs were acquired ([Fig. 4](#f4-ijo-54-01-0152){ref-type="fig"}). In addition, as [Fig. 5](#f5-ijo-54-01-0152){ref-type="fig"} presents, only four gene intersections were identified in DEGs of ESCA and target genes of the 9 second screening drugs, which was a preliminary indication that no significant difference in expression of the drug-associated target genes in ESCA was identified.

Network of drug candidates-target genes-ESCA-associated hub genes
-----------------------------------------------------------------

### Gene association analysis

A total of 70 target genes of drugs and 11 hub genes were united for further analysis. Interactions of the relevant genes were identified in the second PPI network. According to [Fig. 6](#f6-ijo-54-01-0152){ref-type="fig"} (with the green circles representing target genes of predicted drugs and yellow circles representing the hub genes of ESCA), 51 genes were considered to be connected and met the criteria of having been confirmed by other experiments and databases. Acetazolamide and dequalinium were eliminated because their target genes were considered meaningless through PPI analysis, thus the other 7 drugs which were relevant to the aforementioned 51 genes were consequently considered as drug candidates of ESCA. As indicated in [Fig. 7](#f7-ijo-54-01-0152){ref-type="fig"}, associations among the 7 predicted drug candidates-target genes-ESCA-associated hub genes were revealed via network construction, in which the red oblongs represent drug candidates, yellow circles represent 44/51 selected genes (which were also target genes of drug candidates) and blue polygons represent the other 7 genes also belonging to ESCA-associated hub genes.

### Functional analysis of genes

The 51 selected genes were identified to participate principally in 10 pathways, including drug metabolism (cytochrome P450), colorectal cancer and the estrogen signaling pathway ([Table I](#tI-ijo-54-01-0152){ref-type="table"}), on the basis of KEGG analysis (P\<0.001), as well as 9 pathways on the basis of PANTHER analysis (P\<0.05), which, significantly, included the cholecystokinin receptor (CCKR) signaling map and apoptosis signaling pathway (P\<0.01; [Table II](#tII-ijo-54-01-0152){ref-type="table"}). GO annotation analysis indicated that the results of BP, CC, and MF classification were almost the same as the results of the previous analysis for DEGs of ESCA ([Fig. 8](#f8-ijo-54-01-0152){ref-type="fig"}). At this point, although 66/70 drug-associated target genes were not differentially expressed in ESCA, they may be regulated by several drugs in order to affect the pathways, including arachidonic acid metabolism, drug metabolism (cytochrome P450) or CCKR signaling map, as well as BP, CC or MF, particularly when regulated by the drug candidates that affect the group of 51 connected genes. Once the drug candidate-associated genes were directly associated with those ESCA hub genes, we hypothesized that they would participate in some way in ESCA pathogenesis. In such a situation, according to the results of the present study, the predicted drugs could associate with ESCA.

### Molecular docking between drug candidates and hub genes

Docking results are presented in [Table IV](#tIV-ijo-54-01-0152){ref-type="table"}, among which *SPP1* and *CXCL10* were eliminated because of unspecified protein structures. The binding affinity between the predicted drug candidates and hub genes was evaluated by the docking scores. The score reported by the docking approach in systemsDock is a negative logarithm of experimental dissociation/inhibition constant value (p*K*~d~/p*K*~i~), usually ranging between 0 and 10 (i.e., from weak to strong binding), allowing a straightforward indication of binding strength. According to [Table IV](#tIV-ijo-54-01-0152){ref-type="table"}, which lists strength by a decreasing docking score, the molecular docking pairs with a docking score of \>5.52 were attributed to drugs including apigenin, Prestwick-685 and menadione, which overall had the top three scores in the CMAP results. The significant results were plotted by respectively selecting the top three proteins for apigenin, Prestwick-685 or menadione ([Figs. 9](#f9-ijo-54-01-0152){ref-type="fig"} and [10](#f10-ijo-54-01-0152){ref-type="fig"}). A flow chart of the methodology used in the present study is summarized in [Fig. 11](#f11-ijo-54-01-0152){ref-type="fig"}.

Discussion
==========

In the present study, 827 DEGs of ESCA were identified, including 375 upregulated genes and 452 downregulated genes, of which the functions were analyzed. On the basis of the PPI network, 11 hub genes were extracted. To acquire potential drugs for ESCA chemotherapy, the DEGs were uploaded to CMAP and 15 drugs were selected by scores. Furthermore, 9/15 drugs were identified to target 70 genes in total. However, only four gene intersections were identified in DEGs of ESCA and 70 target genes. Acetazolamide and dequalinium were also eliminated by another PPI analysis. As a result, apigenin, baclofen, Prestwick-685, menadione, butyl hydroxybenzoate, gliclazide and valproate were considered as the potential drug candidates, and the network of 7 predicted drug candidates-target genes-ESCA-associated hub genes was constructed. Furthermore, apigenin, Prestwick-685 and menadione were considered significant drug candidates by performing molecular docking.

Thus, considering the research design, three steps were taken to obtain the drug candidates for ESCA. First, full use was made of the CMAP, and the first 15 screening drugs were extracted by scores of \<−0.85. CMAP is an online database that provides an approach to identifying the connections between small molecules, genes and diseases. It was created by the CMAP team at the Broad Institute and the resource is publicly available ([portals.broadinstitute.org/cmap](http://portals.broadinstitute.org/cmap)) ([@b26-ijo-54-01-0152]). In CMAP, drug signatures are ordered lists of genes that are stored following the profiling of 564 drug-treated instances and identified by a computer program. Therefore, the CMAP can significantly increase the rate of drug discovery and identify novel uses for existing drugs. For example, Wang *et al* ([@b38-ijo-54-01-0152]) investigated candidate drugs for hepatocellular carcinoma in the CMAP by analyzing associated subpathways. The CMAP also assisted with the identification of similar signatures of atypical meningiomas and provision of novel treatment methods ([@b39-ijo-54-01-0152]). Additionally, Liu *et al* ([@b40-ijo-54-01-0152]) used CMAP to identify some potential compounds for treating patients with B-cell chronic lymphocytic leukemia (B-CLL) on the basis of altered pathways in B-CLL. Similarly, in the present study, when 375 upregulated genes and 452 downregulated genes of ESCA were uploaded as a probe set to interrogate the CMAP, this dataset was matched with the drugs identified using a Kolmogorov-Smirnov statistical test. The drugs were sorted by their connectivity scores, which was the combination of the up score and down score. The criterion of a score of \<−0.85 was also used to combine a high negative up score and a high positive down score, indicating that the corresponding perturbagen repressed the expression of the probe sets in the up genes list, whereas it induced the expression of the probe sets in the down genes list. Secondly, 6 drugs were eliminated when the standard of STITCH was uniformly adapted. Thirdly, a new PPI analysis was used to establish an association between target genes predicted by the second screening drugs and DEGs of ESCA previously obtained from TCGA and GTEx databases, of which the indicators were artificially set with 'experiments' and 'database' for a higher reliability. Therefore, those drugs corresponding to the certified associated genes were finally retained as potential drug candidates for ESCA.

The retrieval of relevant literature on drug candidates was required to further understand their research status and clinical application, as well as support the prediction. Among the 7 predicted drugs, apigenin is a natural product that is present in a number of plants. It was confirmed to have an anticancer effect on different types of cancer ([@b41-ijo-54-01-0152]-[@b45-ijo-54-01-0152]). Apigenin was once reported to induce apoptosis in ESCA cells through destruction of the membrane structure ([@b46-ijo-54-01-0152]). As Yan *et al* ([@b47-ijo-54-01-0152]) summarized, apigenin may be an adjuvant chemotherapeutic agent for cancer therapy by modulating the phosphoinositide 3-kinase/protein kinase B, mitogen-activated protein kinase/extracellular-signal-regulated kinase, Janus kinase/signal transducer and activator of transcription, nuclear factor-κB (NF-κB), and Wnt/β-catenin signaling pathways. In addition, it was also reported that apigenin may have a further function in cancer chemoprevention via the induction of apoptosis and autophagy ([@b48-ijo-54-01-0152]).

Baclofen is commonly used for treating spastic movement disease ([@b49-ijo-54-01-0152],[@b50-ijo-54-01-0152]). However, baclofen may help to inhibit hiccups following the insertion of a stent for ESCC, according to a case report ([@b51-ijo-54-01-0152]), and it was suggested that it may be a useful adjuvant analgesic for decreasing cancer pain ([@b52-ijo-54-01-0152]). Whether baclofen has any anticancer effects or not remains unknown owing to a lack of relevant research. Prestwick-685, also named clofazimine in PubChem, was identified to be associated with breast cancer ([@b53-ijo-54-01-0152]) and lung cancer ([@b54-ijo-54-01-0152]). Recently, Durusu *et al* ([@b54-ijo-54-01-0152]) provided novel evidence for the anticancer effect of clofazimine, which implies that clofazimine also requires further investigation regarding cancer treatment. Compared with clofazimine, it appears that menadione, which is also known as vitamin K3, has attracted more attention from the perspective of cancer treatment. Menadione has been identified to exhibit significant therapeutic benefits in the treatment of gastric cancer ([@b55-ijo-54-01-0152]), prostate cancer ([@b56-ijo-54-01-0152]), oral cancer ([@b57-ijo-54-01-0152]) and breast cancer ([@b58-ijo-54-01-0152]). Furthermore, the latest research indicated that menadione may increase anticancer activity by combining ROS-generating agents ([@b59-ijo-54-01-0152]), but how it works in ESCA treatment requires further investigation. Butyl hydroxybenzoate, also called butylparaben, is often used as a flavoring additive in food. However, it is reported to participate in a non-genomic mechanism of activation of G-protein-coupled receptor 30 in cancerous and non-cancerous breast cell lines through activation of the extracellular-signal-regulated kinase 1/2 pathway; further research into the carcinogenic action is required ([@b60-ijo-54-01-0152]). Gliclazide is generally used for treating diabetes ([@b61-ijo-54-01-0152],[@b62-ijo-54-01-0152]), but its anticancer effect has seldom been explored ([@b63-ijo-54-01-0152],[@b64-ijo-54-01-0152]). Lastly, valproate has proved to be a potent tool in treating cancer via enhancing doxorubicin cytotoxicity and the efficacy of vinorelbine-cisplatin-based chemoradiation, according to recent studies ([@b65-ijo-54-01-0152]-[@b68-ijo-54-01-0152]). In summary, on the basis of the bioinformatics prediction of the present study and aforementioned studies, apigenin, menadione and valproate are hypothesized to have an increased possibility of becoming the chemotherapeutics for ESCA.

Although a number of the predicted drug candidates for ESCA have not exhibited specific anticancer effects previously, drug repurposing was investigated via efficient bioinformatics analysis and a structure exploration, which means that the excavation of novel drug candidates in the present study was primarily based on the drug repurposing. In particular, the three-step filtering of drug candidates for ESCA executed the drug repurposing simultaneously. In the present study, ESCA was characterized by its DEGs, and the potential effects of drugs were characterized by their target genes. To the extent of searching drugs, the application of extracted DEGs was primarily utilized for screening drugs via CMAP and posteriorly established linkages with drug-associated target genes, which consequently made a connection between ESCA and drugs. In line with this process, the two-time functional analysis of two gene groups, of which one group contains the 827 extracted DEGs of ESCA and the other group contained 51 genes that displayed in the drug candidates-target genes-ESCA-associated hub genes network, explained the underlying pathogenesis of ESCA and predicted the potential influence of drugs. Results of pathway analysis coincided with the arachidonic acid metabolism and drug metabolism (cytochrome P450), on the basis of KEGG analysis, as well as with the CCKR signaling map, on the basis of PANTHER analysis. According to GO analysis, the similar results indicated that, among the drug-associated target genes, 66 unremarkable genes in ESCA, particularly those in the group of 51 connected genes, may be regulated by several drugs to affect the BP, CC or MF and were associated with those hub genes of ESCA, which, as a result, may influence ESCA pathogenesis.

In addition to the bioinformatics database analysis, drug repurposing was also investigated via structure exploration. Docking was used to screen the proteins and identify potential targets for a query ligand ([@b69-ijo-54-01-0152]). Molecular docking is one of the key steps for proper computational reconstruction of actual ligand-receptor or protein-protein interactions, and thus is relevant to drug design and ligands discovery ([@b70-ijo-54-01-0152]-[@b74-ijo-54-01-0152]). In the present study, the binding affinity between drug molecules and proteins was determined. Apigenin, Prestwick-685 and menadione were predicted to be potential drugs that may affect the target genes, together with ESCA-associated hub genes that influence pathogenesis. Higher linking affinity in this step to hub genes in the network confirmed apigenin, Prestwick-685 and menadione to be significant drug candidates, as well as confirmed the CMAP results. Therefore, in taking full advantage of databases and molecule docking, drug repurposing of Prestwick-685 and menadione was achieved, as apigenin has been reported to induce apoptosis in ESCA cells ([@b46-ijo-54-01-0152]). Thus, Prestwick-685 and menadione were considered to be significant novel drug candidates.

Furthermore, the biological significance of five vital hub genes, including *STAT1*, matrix *MMP9*, *TIMP1*, *IL1B* and *IL8*, for ESCA can be explained. According to previous studies ([@b75-ijo-54-01-0152]), *STAT1* was reported to be a tumor suppressor in ESCC by downregulating the activity of NF-κB and STAT3, and it was associated with the substantial downregulation of several pro-survival proteins such as B-cell lymphoma (Bcl)-2, Bcl-extra-large and survivin, as well as modulation of two G1 cell-cycle-regulatory proteins, p21^waf1^ and cyclin D1 ([@b76-ijo-54-01-0152]). *MMP9* was also demonstrated to be a prognostic factor in ESCA ([@b77-ijo-54-01-0152]), and *MMP9* upregulated by protein tyrosine kinase 7 through activation of activator protein 1 and NF-κB could increase the invasive properties of ESCC cells ([@b78-ijo-54-01-0152]). Studies have identified that high serum levels of *TIMP1* were associated with tumor progression and unfavorable prognosis in patients with ESCA ([@b79-ijo-54-01-0152],[@b80-ijo-54-01-0152]). For *IL1B*, it was only reported that the rs16944 G\>A polymorphism may contribute to ESCC susceptibility ([@b81-ijo-54-01-0152]). For *IL8*, it is significantly upregulated during esophageal carcinogenesis, and the IL-8/CXC chemokine receptor 2 signaling pathway is a potential therapeutic target in EAC ([@b82-ijo-54-01-0152]). To summarize, the significant biological functions of *STAT1*, *MMP9*, *TIMP1*, *IL1B* and *IL8* in ESCA provided solid reasons for their being therapeutic targets for patients with ESCA, for which the novel drug candidates may serve certain positive functions in the molecular docking, as predicted.

The present study had certain limitations. The results relied heavily on the bioinformatics database and thus were significantly influenced by the refresh rate of data. Furthermore, drug experiments were not performed, meaning that the predicted drugs may lack effective verification. Despite the limitations, however, full use was made of the DEGs of ESCA in CMAP, STITCH, PPI network and molecular docking, as well as functional analysis including KEGG, PANTHER and GO analysis, to screen for novel drug candidates for ESCA and have confirmed their potential therapeutic effect at a bioinformatics level. Thus, to a certain extent, the present study may provide a reference for the chemotherapy of ESCA, in its molecular biology and methodology, which similar studies have not yet reported. Furthermore, the results require further investigation, as well as *in vivo* studies.
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![GO analysis of the differentially expressed genes of ESCA (\|log~2~ fold-change\| ≥2). Red bars, Biological Process; blue bars, Cellular Component; green bars, Molecular Function. GO, Gene Ontology; ESCA, esophageal carcinoma.](IJO-54-01-0152-g01){#f2-ijo-54-01-0152}

![Protein-protein interaction network of differentially expressed genes of esophageal carcinoma based on Search Tool for the Retrieval of Interacting Genes. The network is presented with an attribute circle layout. Blue lines indicate edges between nodes; yellow circles indicate hub gene nodes (*ELN, TIMP1, ICAM1, TOP2A, IL1B, COL1A1, IL8, MMP9, SPP1, STAT1* and *CXCL10*); gray circles indicate other nodes. Hub genes were extracted with all degrees ≥30.](IJO-54-01-0152-g02){#f3-ijo-54-01-0152}

![Target genes of 9 second screening drugs based on Search Tool for Interactions of Chemicals. (A) Apigenin; (B) Prestwick-685 (clofazimine); (C) menadione; (D) baclofen; (E) dequalinium chloride (dequalinium); (F) butyl hydroxybenzoate (butylparaben); (G) acetazolamide; (H) gliclazide; (I) valproic acid (valproate).](IJO-54-01-0152-g03){#f4-ijo-54-01-0152}

![Intersection of 827 DEGs of ESCA and 70 target genes of 9 second screening drugs. DEG, differentially expressed gene; ESCA, esophageal carcinoma.](IJO-54-01-0152-g04){#f5-ijo-54-01-0152}

![Protein-protein interaction network of ESCA-associated hub genes and drug-associated target genes based on STRING. All the 51 connected nodes were confirmed by Experiments and Databases of STRING. Unassociated nodes are hidden. The green circle represents target genes of predicted drug candidates, whereas the yellow circle represents the hub genes of ESCA. ESCA, esophageal carcinoma; STRING, Search Tool for the Retrieval of Interacting Genes.](IJO-54-01-0152-g05){#f6-ijo-54-01-0152}

![Network of drug candidates-target genes-ESCA-associated hub genes. Red oblongs represent predicted drug candidates; yellow circles represents 44/51 selected genes, which were also target genes of goal drugs; blue polygons represent the other 7 genes also belonging to ESCA-associated hub genes. ESCA, esophageal carcinoma.](IJO-54-01-0152-g06){#f7-ijo-54-01-0152}

![GO analysis of 51 genes, including 44 potential drug-associated target genes and 7 ESCA-associated hub genes. Red bars, Biological Process; blue bars, Cellular Component; green bars, Molecular Function. GO, Gene Ontology; ESCA, esophageal carcinoma.](IJO-54-01-0152-g07){#f8-ijo-54-01-0152}

![Three-dimensional structures of the significant test ligand (residue)-protein based on systemDock. (A) Apigenin-STAT1; (B) apigenin-tissue inhibitor of metalloproteinase 1; (C) apigenin-MMP9; (D) Prestwick-685-STAT1; (E) Prestwick-685-MMP9; (F) Prestwick-685-IL-1B; (G) menadione-STAT1; (H) menadione-MMP9; (I) menadione-IL-1B. STAT1, signal transducer and activator of transcription 1; MMP9, matrix metalloproteinase 9; IL-1B, interleukin 1B.](IJO-54-01-0152-g08){#f9-ijo-54-01-0152}

![Two-dimensional structures of the significant test ligand (residue)-protein based on systemDock. (A) Apigenin-STAT1; (B) apigenin-tissue inhibitor of metalloproteinase 1; (C) apigenin-MMP9; (D) Prestwick-685-STAT1; (E) Prestwick-685-MMP9; (F) Prestwick-685-IL-1B; (G) menadione-STAT1; (H) menadione-MMP9; (I) menadione-IL-1B. STAT1, signal transducer and activator of transcription 1; MMP9, matrix metalloproteinase 9; IL-1B, interleukin 1B.](IJO-54-01-0152-g09){#f10-ijo-54-01-0152}

![Flow chart of the methodology used. The blue boxes represent the process, the green boxes represent the screening drugs, and the yellow boxes represent the other results for corresponding processes. The red dotted line indicates the drug screening process.](IJO-54-01-0152-g10){#f11-ijo-54-01-0152}

###### 

Two-time Kyoto Encyclopedia of Genes and Genomes analysis.

  Group   Gene set   Description                                            P-value       FDR           Overlapping genes
  ------- ---------- ------------------------------------------------------ ------------- ------------- --------------------------------------------------------------------------------------------------------------------
  A       hsa04974   Protein digestion and absorption                       2.45×10^−7^   7.41×10^−5^   10008, 10136, 1277, 1278, 1281, 1282, 1284, 1289, 1300, 2006, 477, 5644, 5645, 643834, 643847
          hsa04512   ECM-receptor interaction                               1.61×10^−5^   2.44×10^−3^   1277, 1278, 1282, 1284, 3655, 3679, 3685, 3691, 375790, 3918, 6696, 7148
          hsa04610   Complement and coagulation cascades                    5.86×10^−5^   5.92×10^−3^   1675, 2149, 2151, 5054, 5055, 5265, 5328, 5329, 713, 714, 730
          hsa05146   Amebiasis                                              1.20×10^−4^   9.06×10^−3^   1277, 1278, 1281, 1282, 1284, 2919, 3553, 3576, 3918, 5275, 6317, 6318
          hsa00590   Arachidonic acid metabolism                            2.01×10^−4^   1.22×10^−2^   100137049, 1571, 239, 247, 2878, 50487, 5320, 5730, 874
          hsa00982   Drug metabolism: Cytochrome P450                       5.09×10^−4^   2.04×10^−2^   125, 131, 1571, 218, 222, 2327, 2946, 316, 54577
          hsa04062   Chemokine signaling pathway                            5.22×10^−4^   2.04×10^−2^   10563, 2919, 2921, 3576, 3579, 3627, 4067, 4283, 6358, 6362, 6363, 6364, 6366, 6373, 6772, 9560
          hsa04933   AGE-RAGE signaling pathway in diabetic complications   5.38×10^−4^   2.04×10^−2^   1277, 1278, 1281, 1282, 1284, 3383, 3553, 3576, 5054, 5292, 6772
          hsa00980   Metabolism of xenobiotics by cytochrome P450           7.70×10^−4^   2.59×10^−2^   125, 131, 1571, 218, 222, 2946, 29785, 54577, 874
          hsa04060   Cytokine-cytokine receptor interaction                 1.42×10^−3^   4.30×10^−2^   10563, 2919, 2921, 3553, 3576, 3579, 3624, 3627, 4233, 4283, 51330, 53833, 6358,6362, 6363, 6364, 6366, 6373, 9560
  B       hsa00982   Drug metabolism: Cytochrome P450                       3.84×10^−7^   1.16×10^−4^   1548, 1555, 1559, 316, 4128, 4129, 54658
          hsa05210   Colorectal cancer                                      3.41×10^−6^   4.02×10^−4^   207, 2353, 2932, 54205, 7157, 836
          hsa04915   Estrogen signaling pathway                             4.40×10^−6^   4.02×10^−4^   207, 2099, 2353, 2550, 3763, 4318, 9568
          hsa05161   Hepatitis B                                            5.40×10^−6^   4.02×10^−4^   207, 2185, 2353, 4318, 54205, 6772, 7157, 836
          hsa00380   Tryptophan metabolism                                  6.63×10^−6^   4.02×10^−4^   1545, 316, 4128, 4129, 847
          hsa04668   TNF signaling pathway                                  8.30×10^−6^   4.19×10^−4^   207, 2353, 3553, 3627, 4318, 5743, 836
          hsa05014   Amyotrophic lateral sclerosis                          2.24×10^−5^   9.68×10^−4^   54205, 598, 7157, 836, 847
          hsa04210   Apoptosis                                              4.01×10^−5^   1.52×10^−3^   142, 207, 2353, 54205, 598, 7157, 836
          hsa00590   Arachidonic acid metabolism                            5.82×10^−5^   1.96×10^−3^   1555, 1559, 5319, 5320, 5743
          hsa00830   Retinol metabolism                                     7.32×10^−5^   2.07×10^−3^   1548, 1555, 1559, 316, 54658

Group A contains the differentially expressed genes of ESCA (\|log~2~ fold-change\| ≥2); Group B contains 51 genes including 44 drug candidate-associated target genes and 7 ESCA-associated hub genes. ESCA, esophageal carcinoma; FDR, false discovery rate; ECM, extracellular matrix; AGE, advanced glycation end-products; RAGE, receptor for AGE; TNF, tumor necrosis factor.

###### 

Two-time Protein Annotation Through Evolutionary Relationships analysis.

  Group   Gene set   Description                                                         P-value       FDR           Overlapping genes
  ------- ---------- ------------------------------------------------------------------- ------------- ------------- -------------------------------------------------------------------------------
  A       P00050     Plasminogen-activating cascade                                      2.39×10^−7^   2.70×10^−5^   5328, 4312, 5055, 5054, 4314, 4318, 5329
          P00011     Blood coagulation                                                   1.64×10^−3^   9.25×10^−2^   5328, 5265, 5055, 5054, 2149, 5329
          P00034     Integrin signaling pathway                                          3.46×10^−3^   1.30×10^−1^   10095, 1277, 1281, 1282, 3685, 1278, 1284, 3691, 1289, 3655, 1300, 3679, 3918
          P06959     CCKR signaling map                                                  1.55×10^−2^   4.39×10^−1^   5328, 7031, 5055, 5054, 3685, 4067, 4314, 4316, 2919, 3576, 4953, 4318
          P00031     Inflammation mediated by chemokine and cytokine signaling pathway   1.94×10^−2^   4.39×10^−1^   6366, 10095, 3627, 3576, 239, 3579, 4629, 6362, 72, 6364, 3710, 4776, 9560
  B       P06959     CCKR signaling map                                                  1.00×10^−5^   1.14×10^−3^   2353, 2641, 4318, 6869, 207, 5743, 836, 2932, 598, 2185
          P00006     Apoptosis signaling pathway                                         1.05×10^−3^   5.93×10^−2^   2353, 7157, 207, 836, 54205, 598
          P00029     Huntington disease                                                  1.27×10^−2^   3.88×10^−1^   2353, 7157, 627, 207, 836
          P00036     Interleukin signaling pathway                                       1.62×10^−2^   3.88×10^−1^   2353, 207, 6772, 2932
          P04372     5-Hydroxytryptamine degradation                                     1.71×10^−2^   3.88×10^−1^   4128, 4129
          P04397     p53 pathway by glucose deprivation                                  2.30×10^−2^   4.34×10^−1^   7157, 207
          P00001     Adrenaline and noradrenaline biosynthesis                           3.69×10^−2^   4.78×10^−1^   4128, 4129
          P04393     Ras pathway                                                         4.36×10^−2^   4.78×10^−1^   207, 6772, 2932
          P00020     Fas signaling pathway                                               4.76×10^−2^   4.78×10^−1^   142, 836

Group A contains the differentially expressed genes of ESCA (\|log~2~ fold-change\| ≥2); Group B contains 51 genes including 44 drug candidate-associated target genes and 7 ESCA-associated hub genes. ESCA, esophageal carcinoma; FDR, false discovery rate; CCKR, chole-cystokinin receptor.

###### 

First screening drugs extracted from CMAP (scores \<-0.85).

  No.    CMAP name               Score    STITCH          Canonical SMILES
  ------ ----------------------- -------- --------------- -----------------------------------------------------------------------------------------------------------------
  6817   Verteporfin             −1       Verteporfin     CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C) CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
  4578   Apigenin                −0.964   Apigenin        C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)OC4C(C(C(C(O4)CO)O)O)O)O)O
  4567   Cefixime                −0.912   Cefixime        C=CC1=C(N2\[C@\@H\](\[C@\@H\](C2=O)NC(=O)/C(=N\\OCC(=O)O)/C3=CSC(=N3)N)SC1)C(=O)O
  7382   Prestwick-685           −0.901   Clofazimine     CC(C)N=C1C=C2C(=NC3=CC=CC=C3N2C4=CC=C(C=C4)Cl)C=C1NC5=CC=C(C=C5)Cl
  4662   Menadione               −0.896   Menadione       CC1=CC(=O)C2=CC=CC=C2C1=O
  6313   Baclofen                −0.889   Baclofen        C1=CC(=CC=C1C(CC(=O)O)CN)Cl
  6296   Dequalinium chloride    −0.883   Dequalinium     CC1=\[N+\](C2=CC=CC=C2C(=C1)N)CCCCCCCCCC\[N+\]3=C(C=C(C4=CC=CC=C43)N)C.\[Cl−\].\[Cl−\]
  4647   Butyl hydroxybenzoate   −0.882   Butylparaben    CCCCOC(=O)C1=CC=C(C=C1)O
  4645   Naloxone                −0.876   Naloxone        C=CCN1CCC23C4C(=O)CCC2(C1CC5=C3C(=C(C=C5)O)O4)O
  3556   Verteporfin             −0.868   Verteporfin     CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5C6(C(C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C) CCC(=O)OC)C(=C3C)CCC(=O)O)C=C
  4556   Paroxetine              −0.865   Paroxetine      C1CNCC(C1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4
  1850   Acetazolamide           −0.863   Acetazolamide   CC(=O)NC1=NN=C(S1)S(=O)(=O)N
  5089   Gliclazide              −0.86    Gliclazide      CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
  1155   Valproic acid           −0.859   Valproate       CCCC(CCC)C(=O)O
  2901   Metacycline             −0.855   Methacycline    CN(C)C1C2C(C3C(=C)C4=C(C(=CC=C4)O)C(=C3C(=O)C2(C(=O)C(=C1O)C(=O)N)O)O)O.Cl

CMAP, Connectivity Map; STITCH, Search Tool for Interactions of Chemicals; SMILES, Simplified Molecular-Input Line-Entry System.

###### 

Predicted binding affinity between drug candidates and hub genes.

  Gene      PDB identifier   Test compound                 Docking score (p*K*~d~/p*K*~i~)
  --------- ---------------- ----------------------------- ---------------------------------
  *STAT1*   1BF5             580043: Apigenin              7.866
  *STAT1*   1BF5             2794: Prestwick-685           7.738
  *MMP9*    1ITV             2794: Prestwick-685           6.768
  *TIMP1*   3MA2             580043: Apigenin              6.593
  *MMP9*    1ITV             580043: Apigenin              6.439
  *IL1B*    2NVH             580043: Apigenin              6.422
  *STAT1*   1BF5             4055: Menadione               6.403
  *MMP9*    1ITV             4055: Menadione               5.612
  *IL1B*    2NVH             4055: Menadione               5.592
  *IL8*     1QE6             4055: Menadione               5.431
  *IL1B*    2NVH             2794: Prestwick-685           5.417
  *TIMP1*   3MA2             4055: Menadione               5.191
  *IL8*     1QE6             580043: Apigenin              5.075
  *IL8*     1QE6             2794: Prestwick-685           4.687
  *IL8*     1QE6             3475: Gliclazide              4.617
  *TIMP1*   3MA2             3475: Gliclazide              4.385
  *TIMP1*   3MA2             3121: Valproic acid           4.344
  *STAT1*   1BF5             3121: Valproic acid           4.23
  *MMP9*    1ITV             3121: Valproic acid           4.131
  *IL1B*    2NVH             3121: Valproic acid           4.092
  *IL8*     1QE6             3121: Valproic acid           4.06
  *TIMP1*   3MA2             2794: Prestwick-685           3.802
  *TIMP1*   3MA2             7184: Butyl hydroxybenzoate   3.73
  *IL8*     1QE6             7184: Butyl hydroxybenzoate   3.352
  *IL1B*    2NVH             7184: Butyl hydroxybenzoate   3.148
  *STAT1*   1BF5             7184: Butyl hydroxybenzoate   3.095
  *IL8*     1QE6             2284: Baclofen                2.957
  *IL1B*    2NVH             3475: Gliclazide              2.894
  *MMP9*    1ITV             3475: Gliclazide              2.871
  *MMP9*    1ITV             7184: Butyl hydroxybenzoate   2.742
  *TIMP1*   3MA2             2284: Baclofen                2.734
  *STAT1*   1BF5             3475: Gliclazide              2.695
  *MMP9*    1ITV             2284: Baclofen                2.571
  *IL1B*    2NVH             2284: Baclofen                2.568
  *STAT1*   1BF5             2284: Baclofen                2.371

PDB, Protein Data Bank.
